跳转到主要内容

Incorporating Pragmatic Elements in Study Designs to Enhance Oncology Randomized Clinical Trials

A FRIENDS OF CANCER RESEARCH WHITE PAPER The article explores the complex landscape of determining optimal drug doses in early-phase oncology trials, with a focus on achieving a delicate balance between efficacy and safety. Traditionally centered on the maximum tolerated dose (MTD), contemporary therapies require a paradigm shift towards premarket dose optimization. Guided by Project … Continued

Pharma Focus Europe – Issue03 – 利用人工智能加速药物开发

Authors: Professor Amin Rostami-Hodjegan, Professor Piet van der Graaf This Pharma Focus EU article, co-authored by Amin Rostami-Hodjegan, SVP of Research & Development and CSO at Certara, and Professor Piet van der Graaf, SVP and Head of QSP at Certara, explores the integration of artificial intelligence (AI) in drug discovery, focusing on quantitative systems pharmacology … Continued

创建新型敏感探针底物和温和抑制剂模型,全面预测 tucatinib 的 CYP2C8 相互作用

Authors: Ian E. Templeton, Karen Rowland-Yeo, Hannah M. Jones, Christopher J. Endres, Ariel R. Topletz-Erickson, Hao Sun, Anthony J. Lee A physiologically based pharmacokinetic (PBPK) model was developed to simulate plasma concentrations of tucatinib (Tukysa®) after single-dose or multiple-dose administration of 300 mg BID orally. This PBPK model was subsequently applied…

人工智能应用的监管举措:规范性撰写的影响

医学撰写 | Volume 32, Issue 3 – Artificial Intelligence and Machine LearningAuthor: Anjana Bose AbstractApplications of artificial intelligence (AI)/machine learning (ML) components in drug development are growing exponentially. The trend is expected to continue. The growth has resulted in increased engagements on the part of regulatory agencies to ensure safe and effective use. This … Continued

2 页,共 13 页

沪ICP备2022021526号

Powered by Translations.com GlobalLink OneLink Software